Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 华润双鹤药业股份有限公司拥有84年光辉历史，始创于1939年，原为部队药厂诞生于太行山革命根据地，对外称利华药厂；1949年随军迁京，后更名北京制药厂，发展为国有大型化学药综合制剂企业，奠定北京现代化学制药工业基础；1997年整合优质资产成立双鹤药业，在上交所上市，通过外延扩张成为立足北京、辐射全国的跨地域集团；2010年进入世界500强企业华润集团旗下，2012年更名为华润双鹤，现为华润集团大健康领域业务单元之一。 公司拥有21家子公司，1.1万余名员工，主营业务涵盖新药研发、制剂生产、药品销售、原料药生产及制药装备等方面，具有丰富的产品线和品牌优势、优质的产品质量和成本控制、强大的渠道与终端覆盖及管理能力、国际化优势、富有活力的团队优势和深厚的文化底蕴，经济实力、竞争活力和可持续发展能力位居国内制药公司前列。2022年实现营业收入94.47亿元，净利润12.15亿元。 公司积极布局普仿药业务、输液业务、差异化药业务和创新药业务四大业务平台，深耕慢病、输液、儿科、肾科、精神/神经等领域，进入肿瘤领域，0号、复穗悦、硝苯地平缓释片、匹伐他汀钙片、糖适平、BFS输液、珂立苏、腹膜透析液、丙戊酸镁缓释片等18个重点产品年销售额超亿元。旗下拥有“双鹤及图”“赛科”“湘中”等中国驰名商标，荣获“中国化药企业Top100企业”等多项荣誉。 公司加速创新转型，搭建多个技术平台，产品集群不断丰富，持续加大研发投入，积极与国内外院校、研发机构及制药企业合作，加快产品获取；拥有国内一流的生产制造能力，20家生产基地分布在国内华北、西北、华中、华南等地区的14个省市，构建先进的生产管理体系，质量管理对标国际一流标准；销售网络覆盖全国33个省、直辖市、自治区和特别行政区，在华北、江浙及输液根据地市场有较强的影响力，部分原料药和制剂产品远销国际市场40余个国家，通过丰富的产品支持、贴心周到的营销服务、良好的终端掌控能力和专业化的市场营销团队，与客户携手共赢。 未来，华润双鹤将继续加快创新转型和质量发展，落实华润集团“1246”模式，服务大国民生、打造大国重器，致力成为大众信赖的、创新驱动的世界一流制药企业，为行业发展和大众健康作出更大贡献。
Main Business 加工、制造、销售制剂药品、化学原料药、制药装备。
Legal Representative 赵骞
Top Executives
董事长：陆文超
董事：赵骞,徐辉,林国龙,于舒天,陆文超,白晓松,李向明
独立董事：孙茂竹,陈震,余顺坤,刘宁
Top 5 Shareholder
Shareholder name Nature Holding Date
北京医药集团有限责任公司流通A股60.21%30/09/2024
香港中央结算有限公司流通A股4.05%30/09/2024
中国建设银行股份有限公司－工银瑞信前沿医疗股票型证券投资基金流通A股2.12%30/09/2024
中国工商银行股份有限公司－中欧医疗健康混合型证券投资基金流通A股1.19%30/09/2024
中国农业银行股份有限公司－中证500交易型开放式指数证券投资基金流通A股0.66%30/09/2024
Company Secretary 刘驹
Solicitors 中伦律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 010-64398099
Fax No 010-64398086
Website www.dcpc.com
Email mss@dcpc.com
Company Address
Register: 北京市朝阳区望京利泽东二路1号
Office: 北京市朝阳区望京利泽东二路1号
Listing Date 22/05/1997
Shares Capital
Shares Capital: 1,038,894,722
Total A Share: 1,038,894,722
Listed A Share: 1,027,219,846
Non-tradable A Share: 11,674,876
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 1.300
DPS(RMB)* ¥ 0.257
NBV Per Share(RMB)* ¥ 10.667
Market Capitalization(RMB) 20.503B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.